Nanomaterials to diagnose and treat diseases17 December 2008
Nanomaterials are showing great promise for accurate disease detection and treatment, but once introduced into the patient’s body they should not induce toxicity or adverse reactions, which could potentially arise from their very small size and other characteristics. This is one of many perspectives of the newly established Centre for Pharmaceutical Nanotechnology and Nanotoxicology (CPNN), which will explore new avenues for design and assessment of safe nanomaterials and particles that can target diseased sites and release their therapeutic cargo in a controlled and effective manner. This approach will further enhance the efficacy of modern medicines and can potentially treat difficult diseases with least toxicity. Professor Moein Moghimi (Professor of Biopharmacy and Nanomedicine, Department of Pharmaceutics and Analytical Chemistry) and colleagues have received 28 million DKK (approximately 3.75 million Euros) from the Danish Council for Strategic Research (DSF) to set this Centre. Professor Moghimi will act as the Director of CPNN and Professor Thomas Bjørnholm (Head of the NanoScience Centre) will be the Chair of the Steering Committee. The Centre has a critical mass of academic and industrial expertise and the necessary state-of-the-art bio-nanotechnology tools to perform, thus reinforcing competitiveness at international level. It is envisaged that novel design and safe use of nanomaterial and nanoparticulate delivery systems will give Denmark and EU significant savings in pharmaceutical spending, which continue to grow.
Full release: |
||||||||
|
|
|
|
